Heartland to appeal NAD sweetener decision
This article was originally published in The Tan Sheet
Executive Summary
The maker of xylitol-containing Ideal No Calorie Sweetener says the National Advertising Division's finding against its "More than 99% Natural" claim could deprive consumers of truthful information and "may have dramatic and unintended adverse consequences" for the non-sugar sweetener market. Carmel, Ind.-based Heartland Sweeteners said it will appeal NAD's recommendation to discontinue claims that Ideal is more natural than other no-calorie sweeteners. In a case 1report published Dec. 14, NAD determined that although the synthetic sweetener sucralose makes up less than 1 percent of Ideal's product weight, it accounts for about 80 percent of its sweetness in packet form. Merisant, maker of stevia-based PureVia, brought the challenge to NADYou may also be interested in...
MSF Wants Faster Deployment Of Ebola Vaccine At ‘Fair’ Price
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
Deals Shaping The Medical Industry, December 2019
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November 2019.
Changing China Is Opening Up For Health Care Entrants
The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: